Drugs / BAY2701250
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06048120 | Sep 2023 → May 2025 | pulmonary hypertension | Bayer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY2701250 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06048120 ↗ |
| Route | Intravenous | “Single does, intravenous infusion” NCT06048120 ↗ |